Einfluss von fäkalem Calprotectin auf klinische Entscheidungen bei Patienten mit Morbus Crohn und Colitis ulcerosa

Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn’s disease and ulcerative colitis

by Anna Luisa Bathe
Doctoral thesis
Date of Examination:2021-02-23
Date of issue:2021-02-22
Advisor:PD Dr. Ahmad Amanzada
Referee:PD Dr. Ahmad Amanzada
Referee:Prof. Dr. Reinhard Hilgers
Referee:Prof. Dr. Martin Oppermann
Persistent Address: http://dx.doi.org/10.53846/goediss-8437

 

 

Files in this item

Name:Dissertation_Bathe_eDiss.pdf
Size:822.Kb
Format:PDF

The following license files are associated with this item:

Abstract

English

Faecal calprotectin (FC) seems to be the best available biomarker for the detection of intestinal inflammation in patients with inflammatory bowel disease (IBD). The aim of this study is to clarify whether the measurement of FC has changed the number of ultrasound and endoscopic procedures, drug modifications, as well as FC re-measurements in IBD patients. This retrospective study included 254 IBD patients. Clinical consequences such as carrying out abdominal ultrasound, endoscopy, drug modification or FC re-measurement at the next ambulatory presentation or during in-patient stay were collected. Statistical analysis was performed to determine the association between clinical decision-making and patient’s characteristics, especially FC value. In CD patients with high FC values significantly increased numbers of abdominal ultrasounds, endoscopies and FC re-measurements were noted. In UC patients with high FC values significantly increased numbers of abdominal ultrasounds, drug modifications and FC re-measurements were noted. Measurement of FC may alter physician’s clinical decision-making in IBD patients beside other clinical and diagnostic parameters. Further prospective and survey studies are warranted to evaluate the influence of FC measurement in the daily clinical decisionmaking.
Keywords: Faecal calprotectin
 
Statistik